Source-grounded facts extracted from Amneal Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Amneal Pharmaceuticals, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-06 meeting.
“Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain Broker Non-Votes 293,211,820 409,435 52,156 0”
Amneal Pharmaceuticals, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-05-06 meeting.
“Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 269,089,785 2,577,481 57,507 21,948,638”
Amneal Pharmaceuticals, Inc. shareholders approved Election of director nominees to hold office until the 2027 Annual Meeting at the 2026-05-06 meeting.
“Proposal 1 : To elect the following director nominees to hold office until the 2027 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Deb Autor 250,782,208 20,907,573 34,992 21,948,638 J. Kevin Buchi 247,071,067 24,615,560 38,146 21,948,638 Jeff George 250,652,568 21,032,093 40,112 21,948,638 John Kiely 239,969,127 31,717,386 38,260 21,948,638 Paul Meister 237,733,309 33,950,919 40,545 21,948,638 Ted Nark 265,399,266 6,285,254 40,253 21,948,638 Chintu Patel 270,365,045 1,320,024 39,704 21,948,638 Chirag Patel 270,364,571 1,320,525 39,677 21,948,638 Gautam Patel 270,643,127 1,042,157 39,489 21,948,638 Shlomo Yanai 250,631,212 21,053,488 40,073 21,948,638”
Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: revenue $723 million, net income $62 million, EPS $0.19. Guidance reaffirmed.
“AMNEAL REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS ‒ Q1 2026 Net Revenue of $723 million; GAAP Net Income of $62 million; Diluted Income per Share of $0.19 ‒”
Amneal Pharmaceuticals, Inc. updated its the first quarter ended March 31, 2026 guidance (raised).
“On April 22, 2026, the Company issued a press release announcing its preliminary results for the first quarter ended March 31, 2026.”
Amneal Pharmaceuticals, Inc. entered into Membership Interest Purchase Agreement with Kashiv BioSciences, LLC valued at $375,000,000 in cash (effective 2026-04-21).
“On April 21, 2026, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company” or “Amneal”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”), pursuant to which, among other matters and on the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to acquire from the Sellers 100% of the outstanding membership interests of Kashiv (the “Acquisition”).”
Amneal Pharmaceuticals, Inc. incurred term loan of $134,673,472.50 with JPMorgan Chase Bank, N.A. maturing August 1, 2032.
“the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the "Additional Amendment No. 2 Term Loan")”
Amneal Pharmaceuticals, Inc. amended credit facility of $1,960,076,527.50 with JPMorgan Chase Bank, N.A. at 2.00% (for base rate) and 3.00% (for SOFR) maturing August 1, 2032.
“on a cashless basis, its term loans outstanding immediately prior to the Repricing Amendment (the “Existing Term Loans) into new term loans with an aggregate principal amount of $1,960,076,527.50 (collectively, the “Converted Amendment No. 2 Term Loans”) and (y) the Company incurred a new term loan with an aggregate principal amount of $134,673,472.50 (the “Additional”
Amneal Pharmaceuticals, Inc. amended Amendment No. 2 to Term Loan Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto (effective 2026-02-02).
“On February 2, 2026, Amneal Pharmaceuticals, Inc.’s (the "Corporation") subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Borrower”), and certain of the Company’s subsidiaries, as guarantors, entered into that certain Amendment No. 2 to Term Loan Credit Agreement (the “Repricing Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the Repricing Amendment.”
Amneal Pharmaceuticals, Inc. incurred senior notes of $600 million aggregate principal amount with Wilmington Savings Fund Society, FSB, as trustee and collateral agent at 6.875% maturing August 1, 2032.
“completed the previously announced offering of $600 million aggregate principal amount of 6.875% senior secured notes due 2032 (the “Notes”)”
Amneal Pharmaceuticals, Inc. incurred term loan of $2.1 billion with JPMorgan Chase Bank, N.A., as administrative agent at term SOFR benchmark rate or the base rate, plus an applicable margin, ... subjec maturing August 1, 2032.
“On August 1, 2025, Amneal Pharmaceuticals, Inc.’s (the “Corporation”) subsidiary, Amneal Pharmaceuticals LLC (the “Company” or, the “Issuer”) borrowed $2.1 billion of new seven-year term B loans (the “New Term Loan”) pursuant to an amendment to the Company’s existing term loan credit facility”
Jason Daly changed role as Executive Vice President, Chief Legal Officer & Corporate Secretary at Amneal Pharmaceuticals, Inc..
“The Agreement provides that, as of the Effective Date, Mr. Daly will be employed as the Company’s Executive Vice President, Chief Legal Officer & Corporate Secretary at an annual base salary of $575,000.”
Amneal Pharmaceuticals, Inc. shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-02 meeting.
“Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024: For Against Abstain Broker Non-Votes 279,106,284 624,760 38,456 0”
Amneal Pharmaceuticals, Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2024-05-02 meeting.
“Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 254,365,134 1,199,935 139,222 24,065,209”
Amneal Pharmaceuticals, Inc. shareholders approved Election of director nominees to hold office until the 2025 Annual Meeting of Stockholders at the 2024-05-02 meeting.
“Proposal 1 : To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 253,927,467 1,736,375 40,449 24,065,209”
Amneal Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $659 million, net income $92 million, EPS $0.30. Guidance reaffirmed.
“the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle”
Amneal Pharmaceuticals, Inc. reported full year ended December 31, 2023 results: revenue $2.39 billion, net income GAAP Net Loss of $84 million, EPS Diluted Loss per Share of $0.48. Guidance initiated.
“per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Full Year 2023 Net Revenue of $2.39 billion; GAAP Net Loss of $84 million; Diluted Loss per Share of $0.48 ‒ ‒ Full Year 2023 Adjusted Net Income (1) of $198 million; Adjusted EBITDA (1) of $558 million; Adjusted Diluted”
Amneal Pharmaceuticals, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $617 million, net income GAAP Net Loss of $99 million, EPS Diluted Loss per Share of $0.40. Guidance initiated.
“--- AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ‒ Full Year 2023 Performance Met or Exceeded Financial Guidance Metrics – ‒ Q4 2023 Net Revenue of $617 million; GAAP Net Loss of $99 million; Diluted Loss per Share of $0.40 ‒ ‒ Q4 2023 Adjusted Net Income (1) of $44 million, Adjusted EBITDA (1) of $142 million; Adjusted Diluted EPS (1)”
Amneal Pharmaceuticals, Inc. reported year ended December 31, 2023 results: revenue $2.37 billion - $2.42 billion, EPS $0.51 - $0.58. Guidance reaffirmed.
“Amneal Pharmaceuticals, Inc., a Delaware corporation (the "Company"), reaffirmed guidance with respect to the year ended December 31, 2023, which was previously announced on November 7, 2023 in connection with announcing the Company's third quarter 2023 results: Net revenue $2.37 billion - $2.42 billion Adjusted EBITDA (1) $540 million - $550 million Adjusted diluted EPS (2) $0.51 - $0.58 Operating cash flow (3) $250 million - $280 million Capital expenditures $50 million - $60 million Weighted average diluted shares outstanding (4) Approximately 310 million”
Amneal Pharmaceuticals, Inc. amended term loan with JPMorgan Chase Bank, N.A., as administrative agent.
“On November 14, 2023, the Company, together with certain of the Existing Term Loan Lenders (the “Consenting Lenders”), entered in to an amendment to the Existing Term Loan Credit Agreement (the “Term Loan Amendment”),”
Amneal Pharmaceuticals, Inc. incurred term loan of $2,351,646,740.86 with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent at term SOFR benchmark rate or the base rate, plus an applicable margin maturing May 4, 2028.
“under the Existing Term Loan Credit Agreement is $191,979,259.14 and the aggregate principal amount of New Term Loans outstanding under the New Term Loan Credit Agreement is $2,351,646,740.86. The Existing Term Loan amortizes in equal quarterly installments in an amount equal to 1.00% per annum of the original principal amount thereof, which payments have been reduced”
Amneal Pharmaceuticals, Inc. amended Term Loan Amendment with Consenting Lenders (effective 2023-11-14).
“On November 14, 2023, the Company, together with certain of the Existing Term Loan Lenders (the “Consenting Lenders”), entered in to an amendment to the Existing Term Loan Credit Agreement (the “Term Loan Amendment”)”
Amneal Pharmaceuticals, Inc. entered into New Term Loan Credit Agreement with Consenting Lenders (or their relevant affiliates) and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent (effective 2023-11-14).
“On November 14, 2023, the Company entered into that certain Term Loan Credit Agreement (the “New Term Loan Credit Agreement”) among the Company, as borrower, the Consenting Lenders (or their relevant affiliates) (the financial institutions from time to time party thereto as lenders, collectively, the “New Term Loan Lenders”) and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.”
Amneal Pharmaceuticals, Inc.: Adopted Amended and Restated Certificate of Incorporation of New Amneal, substantially same as Old Amneal's charter except for technical changes under DGCL 251(g) (effective 2023-11-07).
“Upon consummation of the Holding Company Reorganization, the Amended and Restated Certificate of Incorporation of New Amneal (the “ New Amneal A&R Certificate of Incorporation ”) and the Amended and Restated Bylaws of New Amneal (the “ New Amneal A&R Bylaws ”) were the same as the certificate of incorporation and bylaws of Old Amneal immediately prior to consummation of the Holding Company Reorganization, respectively, other than certain technical changes permitted by Section 251(g) of the DGCL. The New Amneal A&R Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on November 7, 2023.”
Amneal Pharmaceuticals, Inc. underwent a change of control involving Amneal NewCo Inc. (closed 2023-11-07).
“Old Amneal became a wholly-owned subsidiary of a new holding company, Amneal NewCo Inc., a Delaware corporation (“ New Amneal ” or the “ Company ”), which replaced Old Amneal as the public company trading on The New York Stock Exchange”
Amneal Pharmaceuticals, Inc. amended Assumed Agreements (including 2018 Incentive Award Plan, outstanding equity awards, indemnification agreements) with Old Amneal, New Amneal, directors and executive officers valued at Assumed by New Amneal; references to Old Amneal changed to New Amneal; New Amneal added as party (effective 2023-11-07).
“Pursuant to the PubCo Merger Agreement, effective as of the Holding Company Reorganization Effective Time, New Amneal assumed, among other agreements, the Amneal Pharmaceuticals, Inc. 2018 Incentive Award Plan (as previously amended and restated) and all outstanding stock options and equity awards granted thereunder, and the indemnification agreements between Old Amneal and the directors and executive officers of Old Amneal (collectively, the “ Assumed Agreements ”).”
Amneal Pharmaceuticals, Inc. entered into Agreement and Plan of Merger (OpCo Merger Agreement) with New Amneal, Amneal Pharmaceuticals LLC (Amneal OpCo), Amneal Merger Sub 2 LLC valued at OpCo Merger - Merger Sub 2 merged with and into Amneal OpCo, resulting in New Amneal directly and in (effective 2023-11-07).
“Immediately thereafter, as part of the Reorganization, pursuant to the Agreement and Plan of Merger (the “ OpCo Merger Agreement ”), dated as of November 7, 2023, among New Amneal, Amneal Pharmaceuticals LLC, a Delaware limited liability company (“ Amneal OpCo ”), and Amneal Merger Sub 2 LLC, a Delaware limited liability company and a wholly-owned subsidiary of New Amneal (“ Merger Sub 2 ”), Merger Sub 2 merged (the “ OpCo Merger ”) with and into Amneal OpCo, which resulted in New Amneal directly and indirectly wholly owning Amneal OpCo.”
Amneal Pharmaceuticals, Inc. entered into Agreement and Plan of Merger (PubCo Merger Agreement) with Old Amneal, New Amneal and Amneal Merger Sub 1 Inc. valued at Holding company reorganization - Merger Sub 1 merged with and into Old Amneal, New Amneal became dir (effective 2023-11-07).
“On November 7, 2023, as part of the Reorganization, Old Amneal implemented a holding company reorganization (the “ Holding Company Reorganization ”) pursuant to the Agreement and Plan of Merger (the “ PubCo Merger Agreement ”), dated as of November 7, 2023, among Old Amneal, New Amneal and Amneal Merger Sub 1 Inc., a Delaware corporation and a wholly-owned subsidiary of New Amneal (“ Merger Sub 1 ”), pursuant to which Merger Sub 1 merged with and into Old Amneal, which resulted in New Amneal becoming the direct parent company of Old Amneal and replacing Old Amneal as the public company trading on the NYSE.”
Amneal Pharmaceuticals, Inc. reported third quarter ended September 30, 2023 results: revenue $620 million, net income $10 million, EPS $0.06.
“the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS ‒ Q3 2023 Net Revenue of $620 million; GAAP Net Income of $10 million; Diluted EPS of $0.06 ‒ ‒ Q3 2023 Adjusted Net Income (1) of $60 million; Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.19 ‒”
Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2023 results: revenue $610 million to $620 million. Guidance raised.
“report actual third quarter 2023 financial results on November 7, 2023. Unaudited Preliminary Financial Results for the Third Quarter Ended September 30, 2023 • Net revenue of $610 million to $620 million, an increase of approximately 13% compared to the third quarter of 2022 • Income before income taxes of $18 million to $28 million, which is substantially higher”
Amneal Pharmaceuticals, Inc. entered into Term Sheet with holders of the Company's Class B Common Stock (the (effective 2023-10-16).
“On October 16, 2023, Amneal Pharmaceuticals, Inc. (the “Company”), Amneal Pharmaceuticals LLC (the “LLC”), and a representative (the “Amneal Group Representative”) of holders of the Company’s Class B Common Stock, par value $0.01 per share (the “Amneal Legacy Group”), executed a binding term sheet (the “Term Sheet”)”
Amneal Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $599 million, net income $12 million, EPS $0.08. Guidance raised.
“AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Full Year Guidance ‒”
Amneal Pharmaceuticals, Inc. shareholders approved To approve the Amended & Restated 2018 Incentive Award Plan at the 2023-05-09 meeting.
“Proposal 4 : To approve the Amended & Restated 2018 Incentive Award Plan: For Against Abstain Broker Non-Votes 215,730,063 15,006,306 456,212 25,513,061”
Amneal Pharmaceuticals, Inc. shareholders approved To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-09 meeting.
“Proposal 3 : To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain Broker Non-Votes 254,931,713 1,641,294 132,635 0”
Amneal Pharmaceuticals, Inc. shareholders approved To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers at the 2023-05-09 meeting.
“Proposal 2 : To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 227,413,821 3,098,184 680,576 25,513,061”
Amneal Pharmaceuticals, Inc. shareholders approved To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified at the 2023-05-09 meeting.
“Proposal 1 : To elect the following director nominees to hold office until the 2024 Annual Meeting of Stockholders and until their respective successors are elected and qualified: For Against Abstain Broker Non-Votes Emily Peterson Alva 229,279,380 1,816,706 96,495 25,513,061 Deb Autor 229,602,211 1,483,770 106,600 25,513,061 J. Kevin Buchi 197,910,568 33,179,505 102,508 25,513,061 Jeff George 198,211,840 32,879,658 101,083 25,513,061 John Kiely 196,066,358 35,022,385 103,838 25,513,061 Paul Meister 212,151,263 18,932,673 108,645 25,513,061 Ted Nark 228,742,967 2,217,364 232,250 25,513,061 Chintu Patel 229,230,849 1,865,246 96,486 25,513,061 Chirag Patel 229,182,342 1,913,165 97,074 25,513,061 Gautam Patel 227,239,534 3,785,347 167,700 25,513,061 Shlomo Yanai 229,147,164 1,938,034 107,383 25,513,061”
Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $558 million, net income $7 million, EPS $0.05. Guidance reaffirmed.
“Q1 2023 Net Revenue of $558 million; GAAP Net Loss of $7 million; Diluted Loss per Share of $0.05 ‒ ‒ Adjusted EBITDA (1) of $116 million; Adjusted Diluted EPS (1) of $0.12 ‒ ‒ Affirming 2023 Full Year Guidance”
Amneal Pharmaceuticals, Inc. reported first quarter ended March 31, 2023 results: revenue $550 million to $560 million. Guidance reaffirmed.
“2023. Unaudited Preliminary Financial Results for the First Quarter Ended March 31, 2023 Based on preliminary financial information, Amneal expects to report: • Net revenue of $550 million to $560 million, an increase of approximately 12% compared to the first quarter of 2022 • Loss before income taxes of $10 million to $0, an improvement of approximately 50%”
Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.21 billion, net income $130 million, EPS $0.86. Guidance initiated.
“Full Year 2022 Net Revenue of $2.21 billion; GAAP Net Loss of $130 million; Diluted Loss per Share of $0.86”
Amneal Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $610 million, net income $4 million, EPS $0.03. Guidance initiated.
“Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03”
Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.15 billion - $2.25 billion, EPS $0.65 - $0.70. Guidance reaffirmed.
“In connection with a presentation to be made at an investor conference on January 10, 2023, Amneal Pharmaceuticals, Inc., a Delaware corporation (the “Company”), reaffirms previously issued guidance with respect to the year ended December 31, 2022, which was previously issued on November 4, 2022 in connection with the Company’s third quarter 2022 results: Full Year 2022 Financial Guidance Net revenue $2.15 billion - $2.25 billion Adjusted EBITDA (1) $500 million - $520 million Adjusted diluted EPS (2) $0.65 - $0.70 Operating cash flow (3) $200 million - $225 million Capital expenditures $65 million - $75 million Weighted average diluted shares outstanding (4) Approximately 305 million”
Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $546 million, net income $3 million, EPS $(0.02). Guidance reaffirmed.
“the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS ‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Full Year Outlook”
Gustavo J. Pesquin was appointed as Executive Vice President and Chief Commercial Officer – Specialty at Amneal Pharmaceuticals, Inc..
“On September 1, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Gustavo J. Pesquin as the Company’s Executive Vice President and Chief Commercial Officer – Specialty, effective September 6, 2022.”
Deborah M. Autor was appointed as Director at Amneal Pharmaceuticals, Inc..
“On July 29, 2022, the Board of Directors (the “ Board ”) of Amneal Pharmaceuticals, Inc. (the “ Company ”) appointed Deborah M. Autor to the Company’s Board.”
Joseph Todisco departed as Executive Vice President, Chief Commercial Officer – Specialty at Amneal Pharmaceuticals, Inc..
“On March 15, 2022, Joseph Todisco, Executive Vice President, Chief Commercial Officer – Specialty for Amneal Pharmaceuticals, Inc. (the “Company”), informed the Company of his decision to step down from his role to pursue another opportunity outside of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.